Growing Healthcare Impact: 25+ Clinical Trials Worldwide
See trial details below: including objective, status, design, endpoint, and more.
Our clinical trials are producing high-quality data for healthcare decision making and helping us to continue to redefine stroke care. They aid us in the evaluation of stroke interventions and disease treatment safety and efficacy.
See trial details below: including objective, status, design, endpoint, and more.
To evaluate if administration of ApTOLL intravenously at different doses is safe and well tolerated compared to placebo when administered with endovascular therapy (EVT)± i.v. rt-PA for treatment of acute ischemic stroke.
Complete
To determine the safety and efficacy of multiple doses of the LT3001 drug product in Acute Ischemic Stroke (AIS) subjects, who are ineligible for thrombectomy or IV tPA, and who have target mismatch profile of ischemic core volume ≤70 mL, mismatch ratio ≥1.2, and mismatch volume ≥5mL.
Ongoing
Determine if Rapid CTP can help physicians accurately predict response to recanalization in AIS patients undergoing endovascular therapy.
Patients with a Target mismatch profile on Rapid who were treated up to 18 hours after stroke onset had a favorable clinical response rate of 83% following reperfusion.
Evaluate if Trevo thrombectomy plus medical management leads to superior clinical outcomes at 90 days as compared to medical management alone in selected AIS patients.
Early termination for efficacy. Highest rate of clinical benefit (36% absolute risk reduction) in any endovascular stroke trial.
Determine if perfusion imaging can help identify which patients, who are ineligible or failed IV tPA, are most likely to benefit from an endovascular clot removal procedure.
Complete
Assess the safety and efficacy of thrombectomy in carefully selected patients in an extended time window.
Stopped for efficacy
Determine if AIS patients selected with significant penumbral mismatch (measured by MRI criteria) will have improved clinical outcomes when given intravenous tissue plasminogen activator (tPA) compared to placebo.
Stopped for efficacy
Determine whether more advanced imaging selection, newer generation devices, and earlier intervention improve outcomes.
Early termination for efficacy. Highest rate of favorable clinical outcome (71%) in any endovascular stroke trial.
Assess the efficacy and safety of intravenous tenecteplase vs. tPA for bridging therapy prior to early window thrombectomy.
Complete
To test the hypothesis that ultra-early minimally invasive haematoma removal in patients with supratentorial ICH within 8 hours of onset will improve functional outcomes compared to standard therapy.
Enrolling
Investigate the relationship between the success of mechanical thrombectomy performed within 6 hours after onset, the rate of good functional outcome at 3 months, and the presence or absence of Target mismatch on acute multimodal imaging.
Complete
To evaluate the efficacy of endovascular treatment in addition to best medical treatment versus best medical treatment on functional outcome at 3 months in patients with an anterior LVO (ICA/M1/Tandem) related large infarction (>70 mL) and a substantial mismatch (ratio>1.4) up to 24 hours after onset.
Start-Up
Assess the efficacy of augmenting CBF to preserve the penumbra in AIS patients.
Enrolling
Evaluate the efficacy of P2Y12 inhibitor (cangrelor) in addition to MT and BMM compared to MT and BMM alone on favorable functional outcome (i.e. mRS ≤ 2) at 3 months, in AIS patients selected on perfusion imaging between 6h and 24h after stroke onset.
Enrolling
Determine if AIS patients due to LVO, treated with combined IV tPA and Solitaire within 6 hours of symptom onset have less stroke-related disability than those patients treated with IV tPA alone.
Complete
Evaluate different imaging selection methodologies and identify which method provides the highest predictive ability in the selection of AIS patients for IAT.
Complete
Evaluate the safety and efficacy of endovascular thrombectomy in AIS patients with a large core.
Enrolling
Determine if AIS patients due to LVO, treated with combined IV tPA and Solitaire within 6 hours of symptom onset have less stroke-related disability than those patients treated with IV tPA alone.
Early termination for efficacy. Second highest rate of favorable clinical outcome in any endovascular stroke trial.
Evaluate the efficacy and safety of Tenecteplase compared with placebo in patients with AIS and evidence of salvageable tissue on their baseline imaging.
Enrolling
